SNDX(Syndax Pharmaceuticals, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $139.71M | $0 | $0 | $23.68M | $172.35M |
| 毛利润 | — | — | — | — | — |
| 营业利润 | $26.22M | −$151.76M | −$229.95M | −$339.67M | −$273.08M |
| 净利润 | $24.93M | −$149.34M | −$209.36M | −$318.76M | −$285.42M |
| 经营现金流 | $29.13M | −$133.68M | −$160.60M | −$274.90M | −$322.98M |
| 自由现金流 | $29.00M | −$133.68M | −$160.60M | −$274.90M | −$323.17M |
| 摊薄每股收益 | $0.46 | $-2.46 | $-2.98 | $-3.72 | $-3.29 |